Global impact of bronchiectasis and cystic fibrosis

Margarida Redondo, Holly Keyt, Raja Dhar, James D Chalmers, Margarida Redondo, Holly Keyt, Raja Dhar, James D Chalmers

Abstract

Educational aims: To recognise the clinical and radiological presentation of the spectrum of diseases associated with bronchiectasis.To understand variation in the aetiology, microbiology and burden of bronchiectasis and cystic fibrosis across different global healthcare systems.

Bronchiectasis is the term used to refer to dilatation of the bronchi that is usually permanent and is associated with a clinical syndrome of cough, sputum production and recurrent respiratory infections. It can be caused by a range of inherited and acquired disorders, or may be idiopathic in nature. The most well recognised inherited disorder in Western countries is cystic fibrosis (CF), an autosomal recessive condition that leads to progressive bronchiectasis, bacterial infection and premature mortality. Both bronchiectasis due to CF and bronchiectasis due to other conditions are placing an increasing burden on healthcare systems internationally. Treatments for CF are becoming more effective leading to more adult patients with complex healthcare needs. Bronchiectasis not due to CF is becoming increasingly recognised, particularly in the elderly population. Recognition is important and can lead to identification of the underlying cause, appropriate treatment and improved quality of life. The disease is highly diverse in its presentation, requiring all respiratory physicians to have knowledge of the different "bronchiectasis syndromes". The most common aetiologies and presenting syndromes vary depending on geography, with nontuberculous mycobacterial disease predominating in some parts of North America, post-infectious and idiopathic disease predominating in Western Europe, and post-tuberculosis bronchiectasis dominating in South Asia and Eastern Europe. Ongoing global collaborative studies will greatly advance our understanding of the international impact of bronchiectasis and CF.

Conflict of interest statement

Conflict of interest Disclosures can be found alongside this article at breathe.ersjournals.com

Figures

Figure 1
Figure 1
Radiological heterogeneity of bronchiectasis. Two patients are shown: a) a patient with moderate idiopathic bronchiectasis demonstrating predominantly cylindrical dilatation, and b) a patient with severe disease and Pseudomonas aeruginosa colonisation demonstrating widespread varicose and cystic bronchial dilatation.
Figure 2
Figure 2
High-resolution CT scanning in a 27 year old patient with homozygous ΔF508 CF. Bilateral upper lobe bronchiectasis is evident, with mosaicism. The scan also showed extensive emphysema.
Figure 3
Figure 3
Two images from the same individual with tracheobronchomegaly showing a) gross tracheal dilatation and b) severe central bronchiectasis.
Figure 4
Figure 4
Venn diagram illustrating the overlap between COPD, asthma and bronchiectasis.

References

    1. Pasteur MC, Bilton D, Hill AT. British Thoracic Society guideline for non-CF bronchiectasis. Thorax 2010; 65: Suppl., i1–i58.
    1. Chalmers JD, Aliberti S, Blasi F. Treatment of bronchiectasis in adults. Eur Respir J 2015; 45: 1446–1462.
    1. Amaral RH, Schuler Nin C, de Souza VV, et al. . Computed tomography in the diagnosis of bronchiectasis. Eur Respir J 2015; 46: 576–577.
    1. Matsuoka S, Uchiyama K, Shima H, et al. . Bronchoarterial ratio and bronchial wall thickness on high-resolution CT in asymptomatic subjects: correlation with age and smoking. AJR Am J Roentgenol 2003; 180: 513–518.
    1. Reiff DB, Wells AU, Carr DH, et al. . CT findings in bronchiectasis: limited value in distinguishing between idiopathic and specific types. AJR Am J Roentgenol 1995; 165: 261–267.
    1. Chalmers JD, McHugh BJ, Doherty CJ, et al. . Vitamin-D deficiency is associated with chronic bacterial colonisation and disease severity in non-CF bronchiectasis. Thorax 2012; 68: 39–47.
    1. Bronchiectasis In: Gibson J, Loddenkemper R, Sibille Y, et al., eds. The European Lung White Book. 2nd Edn Sheffield, European Respiratory Society, 2013; pp. 176–183.
    1. Burgel PR, Bellis G, Olesen HV, et al. . Future trends in cystic fibrosis demography in 34 European countries. Eur Respir J 2015; 46: 133–141.
    1. Stephenson AL, Tom M, Berthiaume Y, et al. . A contemporary survival analysis of individuals with cystic fibrosis: a cohort study. Eur Respir J 2015; 45: 670–679.
    1. Barr HL, Halliday N, Cámara M, et al. . Pseudomonas aeruginosa quorum sensing molecules correlate with clinical status in cystic fibrosis. Eur Respir J 2015; 46: 1046–1054.
    1. Chalmers JD, Smith MP, McHugh B, et al. . Short and long term antibiotic therapy reduces airway and systemic inflammation in non-CF bronchiectasis. Am J Respir Crit Care Med 2012; 186: 657–665.
    1. Chalmers JD, Hill AT. Mechanisms of immune dysfunction and bacterial persistence in non-cystic fibrosis bronchiectasis. Mol Immunol 2013; 55: 27–34.
    1. Cole PJ. Inflammation: a two-edged sword – the model of bronchiectasis. Eur J Respir Dis Suppl 1986; 147: 6–15.
    1. Garratt LW, Sutanto EN, Ling KM, et al. . Matrix metalloproteinase activation by free neutrophil elastase contributes to bronchiectasis progression in early cystic fibrosis. Eur Respir J 2015; 46: 384–394.
    1. Kelly MG, Murphy S, Elborn JS. Bronchiectasis in secondary care: a comprehensive profile of a neglected disease. Eur J Intern Med 2003; 14: 488–492.
    1. Lonni S, Chalmers JD, Goeminne PC, et al. . Etiology of non-cystic fibrosis bronchiectasis in adults and its relationship to severity. Ann Am Thorac Soc 2015; 12: 1764–1770.
    1. Chalmers JD, Elborn JS. Reclaiming the name ‘bronchiectasis’. Thorax 2015; 70: 399–400.
    1. McShane PJ, Naureckas ET, Strek ME. Bronchiectasis in a diverse US population: effects of ethnicity on etiology and sputum culture. Chest 2012; 142: 159–167.
    1. Anwar GA, McDonnell MJ, Worthy SA, et al. . Phenotyping adults with non-cystic fibrosis bronchiectasis: a prospective observational cohort study. Respir Med 2013; 107: 1001–1007.
    1. Albrecht C, Ringshausen F, Ott S, et al. . Should all adult cystic fibrosis patients with repeated nontuberculous mycobacteria cultures receive specific treatment? A 10-year case–control study. Eur Respir J 2016; 47: 1575–1577.
    1. Yeung MW, Khoo E, Brode SK, et al. . Health-related quality of life comorbidities and mortality in pulmonary nontuberculous mycobacterial infections: a systematic review. Respirology 2016; 21: 1015–1025.
    1. Wurzel DF, Mackay IM, Marchant JM, et al. . Adenovirus species C is associated with chronic suppurative lung diseases in children. Clin Infect Dis 2014; 59: 34–40.
    1. Verma N, Grimbacher B, Hurst JR. Lung disease in primary antibody deficiency. Lancet Respir Med 2015; 3: 651–660.
    1. Dhasmana DJ, Wilson R. Bronchiectasis and autoimmune disease In: Floto RA, Haworth CS, eds. Bronchiectasis (ERS Monograph). Sheffield, European Respiratory Society, 2011; pp. 192–210.
    1. Perry E, Stenton C, Kelly C, et al. . RA autoantibodies as predictors of rheumatoid arthritis in non-cystic fibrosis bronchiectasis patients. Eur Respir J 2014; 44: 1082–1085.
    1. Camus PH, Colby TV. Bronchiectasis associated with inflammatory bowel disease In: Floto RA, Haworth CS, eds. Bronchiectasis (ERS Monograph). Sheffield, European Respiratory Society, 2011; pp. 163–177.
    1. Agarwal R, Aggarwal AN, Sehgal IS, et al. . Utility of IgE (total and Aspergillus fumigatus specific) in monitoring for response and exacerbations in allergic bronchopulmonary aspergillosis. Mycoses 2016; 59: 1–6.
    1. Agarwal R, Aggarwal AN, Dhooria S, et al. . A randomized trial of glucocorticoids in acute-stage allergic bronchopulmonary aspergillosis complicating asthma. Eur Respir J 2016; 47: 490–498.
    1. Braido F, Baiardini I, Sumberesi M, et al. . Public awareness of cystic fibrosis: results from a national pragmatic survey. Eur Respir J 2015; 46: 264–267.
    1. Castellani C, Massie J, Sontag M, et al. . Newborn screening for cystic fibrosis. Lancet Respir Med 2016; in press [DOI: ].
    1. George PM, Banya W, Pareek N, et al. . Improved survival at low lung function in cystic fibrosis: cohort study from 1990 to 2007. BMJ 2011; 342: d1008.
    1. Davis PB. Cystic fibrosis since 1938. Am J Respir Crit Care Med 2006; 173: 475–482.
    1. Dilokthornsakul P, Hansen RN, Campbell JD. Forecasting US ivacaftor outcomes and cost in cystic fibrosis patients with the G551D mutation. Eur Respir J 2016; 47: 1697–1705.
    1. Bush A, Cole P, Hariri M, et al. . Primary ciliary dyskinesia: diagnosis and standards of care. Eur Respir J 1998; 12: 982–988.
    1. Turner JA, Corkey CW, Lee JY, et al. . Clinical expression of immotile cilia syndrome. Pediatrics 1981; 67: 805–810.
    1. Lucas JS, Behan L, Dunn Galvin A, et al. . A quality-of-life measure for adults with primary ciliary dyskinesia: QOL-PCD. Eur Respir J 2015; 46: 375–383.
    1. Tobin MJ, Cook PJ, Hutchison DC. Alpha 1 antitrypsin deficiency: the clinical and physiological features of pulmonary emphysema in subjects homozygous for Pi type Z. A survey by the British Thoracic Association. Br J Dis Chest 1983; 77: 14–27.
    1. Parr DG, Guest PG, Reynolds JH, et al. . Prevalence and impact of bronchiectasis in alpha1-antitrypsin deficiency. Am J Respir Crit Care Med 2007; 176: 1215–1221.
    1. Pasteur MC, Helliwell SM, Houghton SJ, et al. . An investigation into causative factors in patients with bronchiectasis. Am J Respir Crit Care Med 2000; 162: 1277–1284.
    1. McShane P, Patel N, MacMahon H, et al. . Bronchiectasis in hematologic malignancy. Chest 2011; 140: 458A.
    1. Morehead RS. Bronchiectasis in bone marrow transplantation. Thorax 1997; 52: 392–393.
    1. Mandal P, Morice AH, Chalmers JD, et al. . Symptoms of airway reflux predict exacerbations and quality of life in bronchiectasis. Respir Med 2013; 107: 1008–1013.
    1. McDonnell MJ, Ahmed M, Das J, et al. . Hiatus hernias are correlated with increased severity of non-cystic fibrosis bronchiectasis. Respirology 2015; 20: 749–757.
    1. Nimmo C, Capocci S, Honeyborne I, et al. . Airway bacteria and respiratory symptoms are common in ambulatory HIV-positive UK adults. Eur Respir J 2015; 46: 1208–1211.
    1. Rossouw TM, Anderson R, Feldman C. Impact of HIV infection and smoking on lung immunity and related disorders. Eur Respir J 2015; 46: 1781–1795.
    1. Verghese A, al-Samman M, Nabhan D, et al. . Bacterial bronchitis and bronchiectasis in human immunodeficiency virus infection. Arch Intern Med 1994; 154: 2086–2091.
    1. Kurin M, Wiesen J, Mehta AC. Yellow nail syndrome: a case report and review of treatment options. Clin Respir J 2015; in press [DOI: 10.1111/crj.12354].
    1. Casso G, Schoettker P. Tracheobronchomegaly. N Engl J Med 2016; 374: e14.
    1. Winter DH, Manzini M, Salge JM, et al. . Aging of the lungs in asymptomatic lifelong nonsmokers: findings on HRCT. Lung 2015; 193: 283–290.
    1. de Marco R, Marcon A, Rossi A, et al. . Asthma, COPD and overlap syndrome: a longitudinal study in young European adults. Eur Respir J 2015; 46: 671–679.
    1. Rodrigo-Troyano A, Suarez-Cuartin G, Peiro M, et al. . Pseudomonas aeruginosa resistance patterns and clinical outcomes in hospitalised exacerbations of COPD. Respirology 2016; in press [DOI: 10.1111/resp.12825].
    1. Blasi F, Chalmers JD, Aliberti S. COPD and bronchiectasis: phenotype, endotype or comorbidity. COPD 2014; 11: 603–604.
    1. Quint JK, Millett ER, Joshi M, et al. . Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 2013: a population based cohort study. Eur Respir J 2016; 47: 186–193.
    1. Hurst JR, Elborn JS, De Soyza A. COPD-bronchiectasis overlap syndrome. Eur Respir J 2015; 45: 310–313.
    1. Hill AT, Pasteur M, Cornford C, et al. . Primary care summary of the British Thoracic Society guideline on the management of non-cystic fibrosis bronchiectasis. Prim Care Respir J 2011; 20: 135–140.
    1. Mao B, Yang JW, Lu HW, et al. . Asthma and bronchiectasis exacerbation. Eur Respir J 2016; 47: 1680–1686.
    1. Paganin F, Seneterre E, Chanez P, et al. . Computed tomography of the lungs in asthma: influence of disease severity and etiology. Am J Respir Crit Care Med 1996; 153: 110–114.
    1. Agusti A, Calverley PM, Celli B, et al. . Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res 2010; 11: 122.
    1. Stewart JL, Maselli DJ, Anzueto A, et al. . Clinical impact of CT radiological feature of bronchiectasis in the COPDgene cohort. Am J Respir Crit Care Med 2012; 185: Suppl., A3656.
    1. Ni Y, Shi G, Yu Y, et al. . Clinical characteristics of patients with chronic obstructive pulmonary disease with comorbid bronchiectasis: a systematic review and meta-analysis. Int J Chron Obstruct Pulmon Dis 2015; 10: 1465–1475.
    1. Goeminne PC, Nawrot TS, Ruttens D, et al. . Mortality in non-cystic fibrosis bronchiectasis: a prospective cohort analysis. Respir Med 2014; 108: 287–296.
    1. Chalmers JD, Goeminne P, Aliberti S, et al. . Derivation and validation of the bronchiectasis severity index: an international multicentre observational study. Am J Respir Crit Care Med 2014; 189: 576–585.
    1. Chalmers JD, McHugh BJ, Doherty C, et al. . Mannose-binding lectin deficiency and disease severity in non-cystic fibrosis bronchiectasis: a prospective study. Lancet Respir Med 2013; 1: 224–232.
    1. van Haren EH, Lammers JW, Festen J, et al. . Bronchial vagal tone and responsiveness to histamine, exercise and bronchodilators in adults with cystic fibrosis. Eur Respir J 1992; 5: 1083–1088.
    1. Rodwell LT, Anderson SD. Airway responsiveness to hyperosmolar saline challenge in cystic fibrosis: a pilot study. Pediatric Pulmonol 1996; 21: 282–189.
    1. Welsh EJ, Evans DJ, Fowler SJ, et al. . Interventions for bronchiectasis: an overview of Cochrane systematic reviews. Cochrane Database Syst Rev 2015; 14: CD010337.
    1. De Soyza A, Pavord I, Elborn JS, et al. . A randomised, placebo-controlled study of the CXCR2 antagonist AZD5069 in bronchiectasis. Eur Respir J 2015; 46: 1021–1032.
    1. Park IK, Olivier KN. Nontuberculous mycobacteria in cystic fibrosis and non-cystic fibrosis bronchiectasis. Semin Respir Crit Care Med 2015; 36: 217–224.
    1. Lucas J, Leigh MW. Diagnosis of primary ciliary dyskinesia: searching for a gold standard. Eur Respir J 2014; 44: 1418–1422.
    1. Loebinger MR, Wells AU, Hansell DM, et al. . Mortality in bronchiectasis: a long-term study assessing the factors influencing survival. Eur Respir J 2009; 34: 843–849.
    1. Sibila O, Suarez-Cuartin G, Rodrigo-Troyano A, et al. . Secreted mucins and airway bacterial colonization in non-CF bronchiectasis. Respirology 2015; 20: 1082–1088.
    1. Mandal P, Chalmers JD, Graham C, et al. . Atorvastatin as a stable treatment in bronchiectasis: a randomised controlled trial. Lancet Respir Med 2014; 2: 455–463.
    1. Rogers GB, Zain NM, Bruce KD, et al. . A novel microbiota stratification system predicts future exacerbations in bronchiectasis. Ann Am Thorac Soc 2014; 11: 496–503.
    1. Finch S, McDonnell MJ, Abo-Leyah H, et al. . A comprehensive analysis of the impact of Pseudomonas aeruginosa colonization on prognosis in adult bronchiectasis. Ann Am Thorac Soc 2015; 12: 1602–1611.
    1. Guan WJ, Chen RC, Zhong NS. The bronchiectasis severity index and FACED score for bronchiectasis. Eur Respir J 2016; 47: 382–384.
    1. Guan WJ, Gao YH, Xu G, et al. . Bronchodilator response in adults with bronchiectasis: correlation with clinical parameters and prognostic implications. J Thorac Dis 2016; 8: 14–23.
    1. Chalmers JD, Polverino E, De Soyza A, et al. . Heterogeneity in bronchiectasis service provision in Europe: baseline data from the European Bronchiectasis Registry (EMBARC). Eur Respir J 2015; 46: Suppl. 59, PA374.
    1. Döring G, Hoiby N, Consensus Study Group. Early intervention and prevention of lung disease in cystic fibrosis: a European consensus. J Cyst Fibros 2004; 3: 67–91.
    1. Smyth AR, Bell SC, Bojcin S, et al. . European Cystic Fibrosis Society standards of care: best practice guidelines. J Cyst Fibros 2014; 13: Suppl., S23–S42.
    1. Ringshausen FC, de Roux A, Diel R, et al. . Bronchiectasis in Germany: a population-based estimation of disease prevalence. Eur Respir J 2015; 46: 1805–1807.
    1. Dimakou K, Triantafillidou C, Toumbis M, et al. . Non CF-bronchiectasis: aetiologic approach, clinical, radiological, microbiological and functional profile in 277 patients. Respir Med 2016; 116: 1–7.
    1. Falzon D, Mirzayev F, Wares F, et al. . Multidrug-resistant tuberculosis around the world: what progress has been made? Eur Respir J 2015; 45: 150–160.
    1. Pym AS, Diacon AH, Tang SJ, et al. . Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis. Eur Respir J 2016; 47: 564–574.
    1. Mehtaa G, Macek M, Mehtaa A. Cystic fibrosis across Europe: EuroCareCF analysis of demographic data from 35 countries. J Cyst Fibros 2010; 9: Suppl., S5–S21.
    1. Begum M, Lwison G, Wright J, et al. . European non-communicable respiratory disease research, 2002–13: bibliometric study of outputs and funding. PLoS One 2016; 11: e0154197.
    1. Cystic Fibrosis Foundation. Patient Registry Annual Data Report 2014. Bethesda, Cystic Fibrosis Foundation, 2015.
    1. Aksamit TR, Carretta E, Daley CL, et al. . The Bronchiectasis Research Registry: a collaborative research cohort for non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2012; 185: Suppl., A3654.
    1. Seitz AE, Olivier KN, Adjemian J, et al. . Trends in bronchiectasis among Medicare beneficiaries in the United States, 2000 to 2007. Chest 2012; 142: 432–439.
    1. Mirsaeidi M, Hadid W, Ericsoussi B, et al. . Non-tuberculous mycobacterial disease is common in patients with non-cystic fibrosis bronchiectasis. Int J Infect Dis 2013; 17: e1000–e1004.
    1. Adjemian J, Olivier KN, Prevots DR. Nontuberculous mycobacteria among patients with cystic fibrosis in the United States: screening practices and environmental risk. Am J Respir Crit Care Med 2014; 190: 581–586.
    1. Tsang KW, Tipoe GL. Bronchiectasis: not an orphan disease in the East. Int J Tuberc Lung Dis 2004; 8: 691–702.
    1. Edwards EA, Asher MI, Byrnes CA. Paediatric bronchiectasis in the twenty-first century: experience of a tertiary children’s hospital in New Zealand. J Paediatr Child Health 2003; 39: 111–117.
    1. Chang AB, Grimwood K, Maguire G, et al. . Management of bronchiectasis and chronic suppurative lung disease in indigenous children and adults from rural and remote Australian communities. Med J Aust 2008; 189: 386–393.
    1. Chan-Yeung M, Lai CKW, Chan K-S, et al. . The burden of lung disease in Hong Kong: a report from the Hong Kong Thoracic Society. Respirology 2008; 13: Suppl., S133–S165.
    1. Tsang KW, Lam SK, Lam WK, et al. . High seroprevalence of Helicobacter pylori in active bronchiectasis. Am J Respir Crit Care Med 1998; 158: 1047–1051.
    1. Palwatwichai A, Chaoprasong C, Vattanathum A, et al. . Clinical, laboratory findings and microbiologic characterization of bronchiectasis in Thai patients. Respirology 2002; 7: 63–66.
    1. Lee YM. The clinical characteristics of patients with non-CF bronchiectasis. Chest 2011; 140: Suppl., 459A.
    1. Tanaka E, Amitani R, Niimi A, et al. . Yield of computed tomography and bronchoscopy for the diagnosis of Mycobacterium avium complex pulmonary disease. Am J Respir Crit Care Med 1997; 155: 2041–2046.
    1. Kabra M, Kabra SK, Ghosh M, et al. . Is the spectrum of mutations in Indian patients with cystic fibrosis different? Am J Med Genet 2000; 93: 161–163.
    1. Yamashiro Y, Shimizu T, Oguchi S, et al. . The estimated incidence of cystic fibrosis in Japan. J Pediatr Gastroenterol Nutr 1997; 24: 544–547.
    1. Bowler IM, Estlin EJ, Littlewood JM. Cystic fibrosis in Asians. Arch Dis Child 1993; 68: 120–122.
    1. Chalmers JD, Aliberti S, Polverino E, et al. . The EMBARC European Bronchiectasis Registry: protocol for an international observational study. ERJ Open Res 2016; 2: 00081–2015.
    1. Viviani L, Zolin A, Mehta A, et al. . The European Cystic Fibrosis Society Patient Registry: valuable lessons learned on how to sustain a disease registry. Orphanet J Rare Dis 2014; 9: 81.
    1. Aliberti S, Masefield S, Polverino E, et al. . Research priorities in bronchiectasis: a consensus statement from the EMBARC Clinical Research Collaboration. Eur Respir J 2016; 48: 632–647.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel